Pharmaceuticals
CBC Healthcare Infrastructure Platform acquires prime industrial land in Shanghai to develop a high-specifications life science park
* 83.76 mu plot within the Life Science zone of the Qingpu Industrial Park, Shanghai Development to include manufacturing facilities and R&D offices SHANGHAI, Oct. 31, 2022 /PRNewswire/ -- CBC Healthcare Infrastructure Platform ("CBC HIP"), the infrastructure arm ofAsia's largest healthcare-de...
2022-11-01 11:00
2304
CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs
SHANGHAI, Oct. 31, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatDr. Sylvie Peltier ("Dr. Peltier") has been appointed as Senior V...
2022-10-31 21:30
3146
Senhwa Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer
TAIPEI and SAN DIEGO, Oct. 31, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced today that their first patient has been successfully dosed, in a phase I c...
2022-10-31 19:00
3034
Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022
HONG KONG, Oct. 30, 2022 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") released the Phase Ib clinical results of Ivonescimab (PD-1/VEGF bi-specific, AK112) in combination with etoposide and carboplatin in first-line treatment of extensive-stage small-cell lung cancer(ES-SCLC), in an oral ...
2022-10-31 08:40
2115
GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT Study Interim Analysis during Breast Cancer Awareness Month 45% change in treatment recommendations when using DCISionRT
CALIFORNIA CITY, Calif., Oct. 30, 2022 /PRNewswire/ -- GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx(TM)), a leader in molecular diagnostics and precision medicine, today announced interim results from the AUSPREDICT registry. Data presente...
2022-10-31 05:00
1907
Nuevocor to Present Pre-clinical Data on its Gene Therapy Candidate for LMNA Dilated Cardiomyopathy at American Heart Association Scientific Sessions 2022
SINGAPORE, Oct. 28, 2022 /PRNewswire/ -- Nuevocor, a pre-clinical stage cardiac gene therapy company, announced today that it will present new preclinical data on its adeno-associated virus (AAV) gene therapy forLMNA dilated cardiomyopathy at the American Heart Association (AHA) Scientific Sessio...
2022-10-28 22:30
3267
LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022
The efficacy and mechanism of NASH microbiome-based therapy for liver fibrosis, steatosis, and inflammation have been confirmed in various animal models SEOUL, South Korea, Oct. 28, 2022 /PRNewswire/ -- LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented ne...
2022-10-28 21:00
2496
Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
BOSTON, Oct. 28, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (STAR: 688302), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, today presented their preclinical results of ...
2022-10-28 20:30
2782
NDA for New Second-Line Indication of CAR T-Cell Therapy Product YIKAIDA (Axicabtagene Ciloleucel Injection) Approved for CDE Review
Fosun Kite to Participate in the Fifth CIIE to Showcase New Options in Cell Therapy SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- October 24 brought good news from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) that the NDA for new second-line indication o...
2022-10-28 01:37
2703
WuXi Biologics Provides Corporate Updates
SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today updated its recent corporate progress. Recent Business Milestone Despite the global dynamic situation and funding challeng...
2022-10-27 22:13
3198
Simcere Receives FDA Clearance of Investigational New Drug Application (IND) for Bi-functional Fusion Protein, SIM0237
Second US IND approval this year for the global pharmaceutical group NANJING, China and BOSTON, Oct. 27, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK), an innovative global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the com...
2022-10-27 21:25
2658
Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US
SUZHOU, China, Oct. 27, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 120 subj...
2022-10-27 21:22
2508
Antengene to Host Research and Development Day on November 15th and 17th, 2022
* Virtual English Session: Tuesday, November 15 at 8:30 AM – 12:00 PM Eastern Time November 15 at 9:30 PM – November 16 at 1:00 AM Beijing Time * Hybrid Mandarin Session in Shanghai: Thursday, November 17 at 1:30 PM – 5:30 PM Beijing Time SHANGHAI and HONG KONG, Oct. 26, 2022 /PRNewswire/ -- An...
2022-10-27 11:07
3729
Samsung Biologics Reports Third Quarter 2022 Financial Results
* Recorded consolidated revenue of KRW 873 billion in Q3'22 * Recorded consolidated operating profit of KRW 324.7 billion in Q3'22 * Started partial operations at Plant 4 within 23 months since groundbreaking as previously committed and launched two new development platforms INCHEON, South K...
2022-10-27 07:35
2474
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting
MELBOURNE, Australia and SAN FRANCISCO , Oct. 26, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation f...
2022-10-26 19:25
2791
Yiling Pharmaceutical Exhibiting its Innovative TCM Products during CHEXPO Macau 2022
SHIJIAZHUANG, China, Oct. 26, 2022 /PRNewswire/ -- CHEXPO Macau 2022 was officially opened onOctober 20, 2022. As one of the top 10 TCM enterprises in China, Yiling Pharmaceutical exhibited a number of its patented TCM and health products during the expo. As an international and frontier city of ...
2022-10-26 16:52
2612
ImmVira announced its signing of Series C+ financing and negotiation with further investors for the round
SHENZHEN, China, Oct. 26, 2022 /PRNewswire/ -- ImmVira announced its successful signing of Series-C+ financing transaction documents with the first batch of investors recently. This round of financing was initiated by China Merchants China Direct Investments Limited with participation of Lifebay ...
2022-10-26 14:26
2454
SK bioscience and CEPI Sign Agreement to Develop mRNA Vaccines
* CEPI supports up to 40 mil. USD for early development of mRNA vaccine platform to SK bioscience; up to a further 100 mil. could be made available for late-stage development. * SK bioscience to secure new vaccines and establish pandemic response system * SK bioscience to enhance human healt...
2022-10-25 20:00
2970
FDA Accepts NMP's Clinical Trial Application for Development of NMK89 as Imaging Agent for Cancer Diagnosis
- Clinical Study Set to Begin, Focusing on Diagnostic Use of Theranostics - TOKYO, Oct. 25, 2022 /PRNewswire/ -- Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company inJapan, is pleased to announce that the U.S. Food and Drug Administration (FDA) has recently accepted NMP's ...
2022-10-25 16:00
2028
WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities
* WuXi Biologics adds further capacity and capability for drug product fill & finish, providing global customers with end-to-end integrated solutions for diversified modalities, including mRNA-LNP HANGZHOU, China, Oct. 23, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading gl...
2022-10-24 08:30
2579
Week's Top Stories
Most Reposted
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 318 media titles]
2026-01-29 15:06
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 309 media titles]
2026-01-27 13:00
Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 294 media titles]
2026-01-27 18:00
Singapore Airshow 2026 Milestone Edition: 20 Years of Shaping the Aerospace Landscape as Asia-Pacific Drives Global Growth
[Picked up by 284 media titles]
2026-02-01 19:35Multi-Award Winning Phuket Marriott Resort & Spa, Merlin Beach: Voted Top 3 Best Family Resort
[Picked up by 283 media titles]
2026-01-30 08:00
